NEWS

After several years of steady growth, Europe’s drug regulators are once again increasing the pace of recommended medicines for approval.   Last year, European authorities recommended 38 new active substances, delivering a second straight year of elevated output. Even so, Europe continues to lag well behind the U.S., which approved 53 novel medicines, roughly 30% more, according to Endpoints News .   As U.S. policymakers weigh whether to adopt foreign-style pricing frameworks

America's biopharmaceutical sector is delivering unprecedented economic impact across the nation. Since January 2025, companies have committed more than $582 billion  to bolster U.S. research and development, expand manufacturing and create jobs in communities nationwide. From cutting-edge manufacturing facilities in the South to next-generation research hubs in the Mid-Atlantic, the life sciences industry is driving local economic growth, creating high-skill jobs and ensurin

We Work For Health Executive Director Dan Leonard recently sat down with Dr. Rachel Brem, Director of the Breast Imaging and Interventional Center at George Washington University and Co-Founder and Chief Medical Officer of the Brem Foundation. Dr. Brem has pioneered multiple breakthrough technologies for early breast cancer detection and brings a unique perspective – both professional and deeply personal – on what it takes to translate medical innovation into life-saving care

According to a recent report from the American Cancer Society, the five-year survival rate for cancer in the United States has significantly improved. In the mid-1970s, only half  of cancer patients would survive five years or more, now seven in 10 survive. Thanks to technological innovation leading to life-saving cures, cancer survival is increasingly achievable. For cancer patients, these medical innovations add years to their lives. The recent study shows remarkable progr

Evidence continues to show that government price control policies like the Inflation Reduction Act (IRA) slow drug innovation, particularly for small molecule medications, which are typically found in pill and tablet form.   Late last year, the University of Chicago’s Kenneth C. Griffin Department of Economics published research revealing unintended consequences of the IRA on oncology drug development. The University of Chicago’s researchers examined 184 cancer drugs approve

This week, two major research reports were released that offer fresh industry insight into China’s rapid biopharma growth and the potential impact on U.S. global competitiveness.   McKinsey & Company  highlighted China’s undisputed foothold as Asia’s innovation leader. As countries like South Korea and India have stood out, combining ambition with strategic investment to build their capabilities, China is responsible for nearly a third of the global pipeline. TD Cowen collec

In April, a bipartisan committee warned Congress that America’s global biosector leadership was potentially on borrowed time, advising that if not for urgent regulatory corrections, China will overtake the U.S. within three years. That same committee has issued an update. The clock is ticking even faster than feared. “Since the publication of that assessment , the trajectory the Commission identified has continued – and in several respects intensified,” said the National Secu

A historic 2025 is coming to a close for America’s biopharmaceutical sector. From coast to coast, dozens of companies announced or broke ground on next-generation research facilities, expanded their stateside manufacturing capacity, and laid the foundation for accelerating medical breakthroughs. According to We Work For Health’s U.S. Biopharma Investment Watch , the industry committed more than $492 billion  in new domestic investment this year. The unprecedented capital depl

Over the past decade, China has executed a sustained, long-range strategy to build a globally competitive biopharmaceutical sector. Through coordinated investment and policy, the country has moved from “me-too” products to cutting-edge therapies, while elevating regulatory and manufacturing standards to global norms. And it’s working.   On Dec. 11, We Work For Health convened a full room of stakeholders for a critical discussion on China’s accelerating biopharmaceutical ambit

We Work for Health's Executive Director Dan Leonard recently sat down with Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum (NMQF), to discuss his organization's work to ensure fair access to life-saving research and emerging treatments as well as what needs to be done to preserve America's innovation leadership.   The discussion highlighted the public health and economic imperatives of maintaining U.S. competitiveness in biopharmaceutical research

Members of the Senate Special Committee on Aging convened last week to hear from witnesses on restoring trust in American-made medicines.   The hearing  highlighted urgent concerns about America’s reliance on foreign nations, particularly China, for critical drug ingredients and finished medications.   Witnesses and lawmakers warned that this dependence is compromising patient safety, national security and supply-chain resilience.   As Senator Scott (R-FL) said in his opening

Chinese biotech stock is reportedly “booming” while outperforming its U.S. counterpart, delivering the latest data point in a worrisome trend for America’s patients, economy, and national security.   According to a recent STAT article , while U.S. biotech stock is up 20% this year, China's is up a whopping 80%. At first glance, this could be dismissed as another short-term spike. Similar ones were observed between 2018 and 2021 when a flurry of Chinese drugmakers launched IPO